AU Patent

AU2024350257A1 — CORTEXOLONE-17α-PROPIONATE FOR TREATING ACNEIFORM ERUPTIONS

Assigned to Cassiopea SpA · Expires 2026-04-09 · 0y expired

What this patent protects

The present disclosure provides a method of treating a cutaneous acneiform eruption in a subject in need thereof. The method comprises topically administering to the subject an effective amount of cortexolone-17α-propionate. The acneiform eruption can comprise a papule, a pustule…

USPTO Abstract

The present disclosure provides a method of treating a cutaneous acneiform eruption in a subject in need thereof. The method comprises topically administering to the subject an effective amount of cortexolone-17α-propionate. The acneiform eruption can comprise a papule, a pustule, a nodule, crust, a cyst, or any combination thereof on an affected area of the subject. The effective amount of cortexolone- 17α-propionate can be administered in a topical pharmaceutical formulation comprising cortexolone-17α- propionate and one or more pharmaceutically acceptable carriers.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024350257A1
Jurisdiction
AU
Classification
—
Expires
2026-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Cassiopea SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.